Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia

被引：0
|
作者：
Brown, Brianne [1 ]
Turkoz, Ibrahim [2 ]
Mancevski, Branislav [3 ]
Mathews, Maju [4 ]
机构：
[1] Janssen Sci Affairs LLC, Sci Affairs, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Biostat, Titusville, NJ USA
[3] Janssen Sci Affairs LLC, Clin Dev, Titusville, NJ USA
[4] Janssen Res & Dev LLC, Global Med Affairs, Titusville, NJ USA
来源：
BIOLOGICAL PSYCHIATRY | 2016年 / 79卷 / 09期
关键词：
Long-acting injectable; Paliperidone palmitate; Duration of illness;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
607
引用
收藏
页码：212S / 212S
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND TOLERABILITY OF LONG-ACTING INJECTABLE PALIPERIDONE PALMITATE IN THE TREATMENT OF DUAL PSYCHOSIS
    Vazquez Vazquez, J. M.
    Gonzalez-Rodriguez, A.
    Sanz Asin, P.
    Vicente Perellon, L.
    Lopez Garcia, F. J.
    Cruz Alonso, C.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [32] Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
    Desai, Mitesh
    Wooller, Annette
    Lignugaris, Arunas
    Gopal, Srihari
    PSYCHOLOGICAL MEDICINE, 2018, 48 (12) : 2098 - 2099
  • [33] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Qian Cai
    Charmi Patel
    Edward Kim
    Nancy Connolly
    Ozgur Tunceli
    Antoine C. El Khoury
    Advances in Therapy, 2019, 36 : 858 - 869
  • [34] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Cai, Qian
    Patel, Charmi
    Kim, Edward
    Connolly, Nancy
    Tunceli, Ozgur
    El Khoury, Antoine C.
    ADVANCES IN THERAPY, 2019, 36 (04) : 858 - 869
  • [35] Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia
    Rosenheck, Robert A.
    Leslie, Douglas L.
    Sint, Kyaw J.
    Lin, Haiqun
    Li, Yue
    McEvoy, Joseph P.
    Byerly, Matthew J.
    Hamer, Robert M.
    Swartz, Marvin S.
    Stroup, T. Scott
    PSYCHIATRIC SERVICES, 2016, 67 (10) : 1123 - 1129
  • [36] A randomized, double-blind study of paliperidone palmitate and risperidone long-acting therapy in schizophrenia
    Pandina, G.
    Lane, R.
    Gopal, S.
    Gassmann-Mayer, C.
    Hough, D.
    Remmerie, B.
    Simpson, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S481 - S482
  • [37] Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal
    Einarson, Thomas R.
    Maia-Lopes, Susana
    Goswami, Pushpendra
    Bereza, Basil G.
    Van Impe, Kristel
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (09) : 913 - 921
  • [38] Efficacy and tolerability of paliperidone palmitate long-acting injectable antipsychotic in first-episode schizophrenic patients
    Petric, D.
    Racki, V.
    Graovac, M.
    Kastelan, A.
    Grahovac, T.
    Vucic-Peitl, M.
    Franciskovic, T.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 150 - 151
  • [39] In vitro and in vivo characterization of Invega Sustenna® (paliperidone palmitate long-acting injectable suspension)
    Li, Ji
    Rodriguez, Antonela
    Wang, Kaikai
    Olsen, Karl
    Wang, Yan
    Schwendeman, Anna
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2025, 207
  • [40] Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics
    Hargarter, Ludger
    Cherubin, Pierre
    Bergmans, Paul
    Keim, Sofia
    Rancans, Elmars
    Bez, Yasin
    Parellad, Eduard
    Carpiniello, Bernardo
    Vidailhet, Pierre
    Schreiner, Andreas
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2015, 58 : 1 - 7
12345